How does the small molecule AGX51 cause the degradation of ID proteins?

Project specs




Robert Benezra



Funding agency

NIH, Breast Cancer Research Foundation, Angiogenex, Inc., Memorial Sloan Kettering Cancer Center




Together with Angiogenex, Inc. Dr Robert Benezra, Member of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center, has identified a small molecule, AGX51, that inhibits ID proteins and disrupts the cellular pathways by which cancers repropagate, and could therefore be an important new anti-tumour therapy.

Researcher Profile

Robert Benezra, PhD, is a Member of the Cancer Biology and Genetics Program at Memorila Sloan Ketter Cancer Center. His work over the past 30 years there has identified the importance of ID proteins in development and their reactivation in a variety of cancers. Recent targeting of ID proteins by small molecules with the help of Angiogenex, Inc has led to the development of novel targeted therapies being readied for clinical application.

Is it more than “just asthma”? Understanding the sources…

Get to know the different Eosinohilic Drive Disease (EDD) which…